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INTRODUCTION
The current opioid epidemic has manifested itself in numerous 
ways, one of which being a dramatic rise in the way patients attempt 
to create a false negative urine drug screen. From urine additives to 
synthetic urines to prosthetics, there is no shortage of options. The 
use of urine analytics for drug screening purposes has been on a con-
tinuous rise since the federal government mandated the screening 
of all federal employees in 1988.1 As is often the case, the market to 
evade this screening protocol, or create a false-negative, has seen a 
similar growth.1-3 This case report focused on synthetic urines while 
on buprenorphine and outlines the numerous ways in which a patient 
attempted to use synthetic urine to create a false negative on her 
urine drug screen.
CASE REPORT
A 35-year-old female with a history of opioid use disorder, benzo-
diazepine dependence, amphetamine abuse, and major depressive 
disorder initially presented to the emergency department (ED) with 
opioid withdrawal symptoms after “running out” of her prescribed 
buprenorphine. The patient was restarted on buprenorphine while 
in the ED and was referred to the hospital’s addiction clinic for 
buprenorphine maintenance where she was followed up the next day 
after discharge. 
Upon initial interaction at her first clinic visit, she reported opiate 
use starting at age 23. She stopped opiate abuse briefly during the 
pregnancies of her five children but would restart after delivery. She 
also reported intermittent amphetamine abuse for chronic fatigue 
and clonazepam to help with sleep and anxiety. The patient was 
followed by another physician at a different facility for her buprenor-
phine that was tapered to 2 mg twice a day for the previous six 
months. She had monthly clinic visits for maintenance treatment 
from her previous physician. She reported being tapered to a lower 
dose, however, she did not reveal her amphetamine abuse leading to 
the taper. She reported stability and requested a month’s supply of 
buprenorphine. We elected to provide the patient with only a week’s 
supply of buprenorphine as we did not get the records from her previ-
ous buprenorphine provider. 
Table 1 shows a series of four clinic visits where it was revealed 
that the patient attempted to create a false negative on her urine drug 
screen through the use of various urine tampering methods. Initially, 
she attempted to use a friend’s urine who was also on buprenorphine, 
but she was not aware that friend was abusing opiates. On subse-
quent visits, she brought in synthetic urine purchased from the local 
gas station, attempting a different tampering method each visit. Her 
second visit was synthetic urine only. The third visit consisted of 
synthetic urine with a buprenorphine tab crushed into the urine. 
Her last urine was her own urine with amphetamines that she was 
attempting to hide.
Table 1. Patient clinic visits and results of labs. 
Clinic 
Visit
Buprenorphine Norbuprenorphine Ratio Opiates Urine 
Source
Day 1 Detected Detected Normal Detected Friend
Day 8 Not detected Not detected NA Not 
detected
Synthetic 
urine
Day 22 Detected Detected Abnormal Negative Synthetic 
Urine with 
Crushed 
Buprenor-
phine
Day 42 Detected Detected Normal Negative Patient’s 
urine 
without 
tampering
The patient revealed all of her attempted urine tampering methods 
after the test results were discussed with her following the Day 22 
clinic visit. While she had not been using opiates, she had continued 
to abuse amphetamines and benzodiazepines and was attempting 
to hide those results. She revealed that this was the reason for her 
being discharged from her previous clinic and explained how she had 
purchased the product at a local gas station and had looked at options 
online. She reported that she used a product called UPass™, but said 
most people call it “Fetish Urine”. 
After revealing the tampering of urine, the patient was seen weekly 
and she slowly stopped use of amphetamines. Her urine drug screens 
revealed normal values of buprenorphine and norbuprenorphine. She 
was stable, participated in clinic and groups, sustained a job, and was 
able to support her kids.
DISCUSSION
A plethora of urine tampering options are available online ranging 
in price and effectiveness. These include synthetic urines, urine addi-
tives, and prosthetics. Synthetic urines claim to be an “exact match” 
to human urine. Some common brand names are: UPass™, Ultimate 
Gold, Ultra-Pure®, Magnum Synthetic™, XStream®, Quick Fix®, Test-
clear, and ClearChoice®.1,3 Additionally, multiple online communities 
(e.g., www.urineluck.com, www.testclean.com, www.peretto.com, 
www.hempusa.com) have open forums that detail stories of using 
synthetic urine and anecdotal reports about which products did and 
did not work. 
The online market includes urine additives, which are less prev-
alent, but clinicians should be aware of them. Online directions 
instruct to add the product to the urine sample and mix the two 
together. Popular brands online include Clean X®, Urine AID (con-
taining glutaraldehyde), Klear and Whizzies (containing nitrite), 
Urine Luck®, Klear II (containing pyridinium chlorchromate, PCC), 
and Stealth™ (containing peroxidase and peroxide). These additives 
promise to “detox” the urine and “destroy unwanted substances.1,3 
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Glutaraldehyde containing substances can cause false negatives 
for tetrahydrocannabinol (THC) and opioids. Nitrites cause false 
negative on immunoassays for THC, cocaine, morphine, amphet-
amines, and phencyclidine and on gas chromatography (GC- MS 
confirmatory test) for THC. PCC can cause immunoassay false nega-
tive for THC and opiates.1
Lastly, the market includes prosthetics, which can be used in 
combination with synthetic urines or on their own, usually with the 
goal of passing a urine test where sampling collection is observed 
directly. Products available include The Whizzinator™, The Urina-
tor™, and Butt Wedge.1-3 The Whizzinator™ employs a prosthetic 
penis to excrete urine. The Urinator™ has a container strapped to 
the body with a heating unit and a tube placed near the urethra. The 
Butt Wedge contains a wedge-shaped container placed between 
users buttocks.1 
While our patient was likely unaware of the specific buprenorphine 
to norbuprenorphine ratios needed to create a “true” false negative, 
physicians should be aware of it. Buprenorphine is a partial agonist at 
the mu opioid receptor and has poor oral bioavailability but extensive 
sublingual bioavailability.5 It is metabolized in the liver by N-dealkyl-
ation and gets converted to a product called norbuprenorphine. Both 
buprenorphine and norbuprenorphine undergo glucuronidation to 
inactive buprenorphine and norbuprenorphine conjugates that are 
excreted in the urine.5 The norbuprenorphine and buprenorphine 
concentration should be measured as presence of both indicates an 
authentic urine. The buprenorphine/norbuprenorphine ratio can 
be 0.2 or more.6 The ratio of buprenorphine to norbuprenorphine 
carries significance when attempting to identify altered urine speci-
mens. Knowledge of these methods of urine drug screen adulteration 
is important for compliance versus noncompliance with treatment, 
diversion risk, and guiding management plans of patients.
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